Repare Therapeutics Inc. (RPTX)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Repare Therapeutics Inc. (RPTX) Reports Break-Even Earnings for Q3
Repare Therapeutics Inc. (RPTX) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to a loss of $0.81 per share a year ago.
Repare Therapeutics Inc. (RPTX) Reports Q2 Loss, Misses Revenue Estimates
Repare Therapeutics Inc. (RPTX) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.56. This compares to a loss of $0.82 per share a year ago.
What Makes Repare Therapeutics (RPTX) a New Buy Stock
Repare Therapeutics (RPTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Repare Therapeutics (RPTX) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Repare Therapeutics (RPTX) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Repare Therapeutics (RPTX) Loses -5.19% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Repare Therapeutics (RPTX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Why Is Repare Therapeutics Stock Trading Lower On Friday?
On Thursday, Repare Therapeutics Inc RPTX revealed data from its MYTHIC Phase 1 gynecologic expansion trial evaluating the combination of lunresertib and camonsertib (Lunre+Camo) for endometrial cancer and platinum-resistant ovarian cancer (PROC) harboring lunre-sensitizing biomarkers.
RPTX Stock Up as Dosing Begins in Solid Tumor Study for Combo Drug
Repare stock gains 8% as the company initiates dosing patients in its phase I study of the RP-3467 combo regimen for advanced solid tumor indications.
Repare: Q4 2024 Is A Major Inflection Point With Lunresertib, Camonsertib Data
Repare Therapeutics Inc. results from phase 1 MYTHIC study, using lunresertib + camonsertib for the treatment of platinum-resistant ovarian and endometrial cancer with genomic alterations, are expected in Q4 of 2024. Preliminary RECIST response data from 10 patients using the lunresertib + camonsertib combination for ovarian and endometrial cancer patients was 50%. The global ovarian cancer market is expected to reach $11.18 billion by 2029.
Repare Therapeutics Inc. (RPTX) Reports Q2 Loss, Lags Revenue Estimates
Repare Therapeutics Inc. (RPTX) came out with a quarterly loss of $0.82 per share versus the Zacks Consensus Estimate of a loss of $0.85. This compares to loss of $0.28 per share a year ago.
Repare (RPTX) Up 14% as Ovarian Cancer Combo Gets Fast Track Tag
Repare (RPTX) rises 14% as the FDA grants Fast Track designation to its investigational lunresertib/camonsertib combo to treat adult ovarian cancer patients in the United States.
